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ABSTRACT 
 
 In mammals, the corpus luteum (CL) is an essential endocrine gland for the 
establishment and maintenance of pregnancy. If pregnancy is not established, the CL 
regresses and disappears rapidly from the ovary (luteolysis). Luteolysis is initiated by 
the uterine prostaglandin F2α (PGF) in ruminants, and luteolysis is characterized by a 
reduction in progesterone (P4) production (functional luteolysis) followed by luteal cell 
death (structural luteolysis). The major event that causes structural luteolysis is luteal 
cell death (apoptosis). Apoptosis is a highly conserved mechanism that allows an 
organism to tightly control cell numbers and tissue size. Luteal regression is triggered 
by complex factors. Many cytokines, including tumor necrosis factor α and interferon γ 
secreted by immune cells, and nitric oxide produced by luteal endothelial cells directly 
induce CL cells to undergo apoptosis. These reports indicate that many molecules are 
involved in structural luteolysis. However, the indirect effects of the above luteolytic 
factors on luteolysis are not well understood. 
Glycosylation modulates a variety of physicochemical and biological properties 
of proteins such as protein folding, stability, targeting, and ligand binding. Most 
membrane proteins including cell surface receptors are glycosylated, and glycosylation 
status is important for their function. However, the role of glycosylation in the CL is not 
clear.  
Galectins are carbohydrate-binding proteins distributed intra- and extracellularly. 
Their carbohydrate-binding specificity for β-galactoside is conserved by evolutionarily 
preserved carbohydrate-recognition domains. Extracellular galectins interact with cell 
surface oligosaccharides and form lattices that enhance the resident time of 
glycoproteins at the cell surface. 
Galectin-3, a ubiquitously expressed protein involved in many cellular processes, 
serves as an anti-apoptotic and/or pro-apoptotic factor in various cell types. Although 
galectin-3 is detected in the bovine CL, its role remains unclear. The expression of 
galectin-3 in the bovine CL was highest at the regressed stage, and galectin-3 was 
localized on luteal steroidogenic cells (LSCs). When cultured LSCs were exposed to 
PGF for 48 h, the expression and secretion of galectin-3 increased. When the cultured 
LSCs were treated with galectin-3 for 24 h, cleaved caspase-3 expression was increased 
and the cell viability was decreased, whereas P4 production did not change. β1 integrin, 
a target protein of galectin-3, was expressed in bovine CL and possessed glycans which 
galectin-3 binds. Furthermore, galectin-3 bound to glycans of luteal β1 integrin. The 
decreased cell viability of cultured LSCs by galectin-3 was suppressed by β1 integrin 
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antibody. The overall findings suggest that the secreted galectin-3 stimulated by PGF 
plays a role in structural luteolysis by binding to β1 integrin. 
Galectin-1 is expressed in the functional CL of cows, and increases the viability 
of bovine LSCs by modifying the functions of membrane glycoproteins. The binding of 
galectin-1 to glycoproteins is blocked by α2,6-sialylation of the terminal galactose 
residues of glycoconjugates, which is catalyzed by a sialyltransferase (ST6Gal-I). 
However, the physiological role of α2,6-sialic acid in the bovine CL is unclear. The 
level of α2,6-sialylation of the bovine CL were higher during the regressed-luteal stage 
than other luteal stages. Lectin histochemistry revealed that α2,6-sialylated 
glycoconjugates were localized to luteal endothelial cells throughout the estrous cycle. 
In addition, α2,6-sialylated glycoconjugates concentrated to the membrane of LSCs 
during the regressed-luteal stage. PGF treatment for 72 h enhanced the expression of 
ST6Gal-I mRNA and the level of α2,6-sialylated glycoproteins in mid-LSCs. The level 
of α2,6-sialylated glycoproteins of late-LSCs (Days 15-17 after ovulation) was higher 
than that of mid-LSCs (Days 8-12 after ovulation), and galectin-1 increased the viability 
of mid-LSCs but not that of late-LSCs. Furthermore, galectin-1 increased the viability 
of late-LSCs when α2,6-sialic acid residues were removed by neuraminidase. The 
overall findings suggest that α2,6-sialylation stimulated by PGF contributes to luteolysis 
by inhibiting the luteotrophic effects of galectin-1 in the bovine CL. 
My study shows that the interaction between galectins and glycan play a critical 
role in the regression of bovine CL. Galectin-3 increased by PGF induced the apoptosis 
of bovine LSCs, and α2,6-sialylated glycoproteins inductively expressed by stimulation 
with PGF2α inhibits the interaction between galectin-1 and the N-glycoproteins on the 
cell surfaces, contribute to the regulation of luteolysis in co
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CHAPTER 1 
Galectin-3 contributes to luteolysis by binding to β1 integrin 
in the bovine corpus luteum 
 
INTRODUCTION 
 
The corpus luteum (CL) is a transient endocrine gland that is essential for the 
regulation of ovarian cycles as well as for the establishment of pregnancy. If pregnancy 
does not occur, regression of the CL (luteolysis) is initiated by the uterine prostaglandin 
F2α (PGF) in ruminants [1]. Luteolysis is characterized by a reduction in progesterone 
(P4) production (functional luteolysis) followed by luteal cell death (structural 
luteolysis) [2]. The major event that causes structural luteolysis is luteal cell death 
(apoptosis) [3-5]. Apoptosis is a highly conserved mechanism that allows an organism 
to tightly control cell numbers and tissue size [6]. Luteal regression is triggered by 
complex factors. Since progesterone is one of the survival factors in the bovine corpus 
luteum [7], functional luteolysis could be a cause of structural luteolysis. Many 
cytokines, including tumor necrosis factor α (TNF) and interferon γ (IFNG) secreted by 
immune cells, and nitric oxide produced by luteal endothelial cells directly induce CL 
cells to undergo apoptosis [8-10]. Nitric oxide is also known to play a crucial role in 
functional luteolysis [11]. These reports indicate that many molecules are involved in 
structural luteolysis. However, the indirect effects of the above luteolytic factors on 
luteolysis are not well understood. 
Galectin-3 is one of the β-galactoside-binding proteins that bind to target 
molecules through conserved carbohydrate recognition domains [12]. In various cell 
types, galectin-3 is expressed in the nucleus or cytoplasm, on the cell membrane, and in 
the extracellular matrix [13]. Galectin-3 is involved in many cellular processes such as 
apoptosis and proliferation [14-16]. Intracellular galectin-3 generally mediates 
anti-apoptotic effects through carbohydrate-independent processes [17-20], whereas 
extracellular galectin-3 binds to cell surface oligosaccharides, and thereby induces 
apoptosis [14, 21, 22].  
Integrins are cell surface glycoproteins that mediate adhesion to the 
extracellular matrix, and integrin signaling regulates cell proliferation, differentiation 
and apoptosis [23]. In mammals, they are composed of 18 α-subunits and 8 β-subunits 
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[24]. Among these integrins, 12 members containing the β1 subunit are involved in 
various biological functions [25]. β1 integrin is a glycan to which galectin-3 binds [26] 
and extracellular galectin-3 induces apoptosis by binding to β1 integrin in T cells and 
tumor cells [14, 22]. Therefore, interaction between galectin-3 and β1 integrin might 
also play a role in inducing apoptosis of luteal cells. 
In cow, galectin-3 has been identified in the uterus, cervix, oviduct, atretic 
follicles and CL [27]. Galectin-3 protein localization has been immunohistochemically 
detected in the regressing CL [27], but its physiological role is still unclear. Based on 
these reports, we hypothesized that galectin-3 is involved in the apoptosis of luteal cells 
during luteolysis. In the present study, to test this hypothesis, we examined 1) cyclic 
changes in the galectin-3 mRNA and protein expressions, 2) effect of luteolytic factors 
on expression of galectin-3 mRNA and protein in cultured mid luteal steroidogenic cells 
(LSCs), 3) subcellular localization of galectin-3 in the regressed CL and effect of PGF 
on the secretion of galectin-3 in LSCs, 4) effect of galectin-3 on P4 production and cell 
viability in LSCs, 5) expression and glycan structure of β1 integrin in bovine CL 
throughout the estrous cycle, 6) interaction between β1 integrin and galectin-3 in LSCs. 
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MATERIALS AND METHODS 
 
Collection of bovine CLs 
Ovaries were collected from Holstein cows at a local slaughter-house within 
10–20 min after exsanguinations. The stage of the estrous cycle was defined as 
described previously [28]. Ovaries with CLs were classified into the early (Days 2-3 
after ovulation), developing (Days 5-6), mid (Days 8-12), late (Days 15-17), and 
regressed (Days 19-21) luteal stages. After determination of the stages, CL tissues were 
immediately separated from the ovaries, frozen rapidly in liquid nitrogen, and then 
stored at −80°C until processed for mRNA and protein analyses. For cell culture, 
ovaries with CLs were submerged in ice-cold physiological saline and transported to the 
laboratory. 
 
Luteal cell isolation 
Luteal tissue from mid- and late-luteal stage CLs was enzymatically 
dissociated, and luteal cells were cultured as described previously [29]. Dissociated 
luteal cells from CLs were pooled. The luteal cells were suspended in a culture medium, 
Dulbecco modified Eagle medium and Ham F-12 medium (D/F; 1:1 [vol/vol]; D8900; 
Sigma-Aldrich Corp., St. Louis, MO, USA) containing 5% bovine serum (16170–078; 
Thermo Fisher Scientific, MA, U.S.A.) and 20 μg/ml gentamicin (15750–060; Thermo 
Fisher Scientific, MA, U.S.A.) under 5% CO2 in air. Cell viability was greater than 85% 
as assessed by trypan blue exclusion. The cells consisted of approximately 70% small 
LSCs, 20% large LSCs, 10% endothelial cells or fibrocytes, and no erythrocytes. In this 
study, these cells were defined as LSCs. 
 
Cell culture 
Dispersed luteal cells (2.0×105 cells/ml) were cultured in D/F medium 
containing 5% bovine serum in 24-well plates (2.0×105 cells/well, 662160; Greiner 
Bio-One, Frickenhausen, Germany) for Quantitative RT-PCR, or 75-cm2 culture flasks 
(12×105 cells/flask, 658175; Greiner Bio-One, Frickenhausen, Germany) for western 
blotting, or 96-well culture dishes (0.2×105 cells/well, 3860–096; Iwaki, Chiba, Japan) 
for cell viability test and EIA. The medium was replaced with D/F medium without 
phenol red (D2906; Sigma-Aldrich Corp., St. Louis, MO, USA) containing 0.1% bovine 
serum albumin (BSA; 23209; Thermo Fisher Scientific, MA, U.S.A.), 5 ng/ml sodium 
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selenite (S5261; Sigma-Aldrich Corp., St. Louis, MO, USA), and 5 μg/ml 
holo-transferrin (T3400; Sigma-Aldrich Corp., St. Louis, MO, USA), and the following 
experiments were carried out. 
 
Quantitative RT-PCR 
Total RNA was extracted from CL tissues and cells using TRIsure 
(BIO-38032; BIOLINE) according to the manufacturer’s directions. One μg of each 
total RNA was reverse transcribed using a ThermoScriptTM RT-PCR System (no. 
11146-016; Invitrogen, Carlsbad, CA, USA), and 10% of the reaction mixture was used 
in each PCR using specific primers for galectin-3 from the bovine sequence (Table 1). 
Quantification of mRNA expression was determined by iQ SYBR Green Supermix (no. 
170-8880; Bio-Rad Laboratories, Inc, Berkeley, CA, USA) starting with 2 ng of 
reverse-transcribed total RNA. For quantification of the mRNA expression levels, and 
PCR was performed under the following conditions: 95°C for 15 min, followed by 45 
cycles of 94°C for 15 sec, 60°C for 20 sec and 72°C for 15 sec. MRPL4 mRNA 
expression was used as an internal control. To analyze the relative level of expression of 
each mRNA, the 2- ΔΔCT method was used [34].  In the present study, we compared 
four housekeeping genes in the CL by real-time PCR. The four genes evaluated were 
mitochondrial ribosomal protein L4 (MRPL4), cytochrome c oxidase subunit IV 
(COX4), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and tubulin beta 2 
(TUBB) (Table 1). To determine the most stable transcribed housekeeping gene, 
Normfinder software (download at http://moma.dk/normfinder-software) was used. This 
software calculates the gene expression stability measure (M) and determines the most 
stable housekeeping gene via a stepwise exclusion or ranking process resulting in the 
selection of the most stable housekeeping genes for the specific tissue. Since MRPL4 
was the most suitable, with an average expression stability of M = 0.171, followed by 
COX4 (M =0.261) > GAPDH (M = 0.762) > TUBB (M = 0.280), MRPL4 was used as a 
housekeeping gene for further experiments. 
 
Western blotting 
Protein concentrations in the lysates were determined by using BSA as a 
standard. The proteins were then solubilized in SDS gel-loading buffer (50 mM 
Tris-HCl, 2% SDS [31607-94, Nacalai Tesque, Tokyo, Japan], 10% glycerol, 1% 
β-mercaptoethanol [137-06862; Wako Pure Chemical Industries, Ltd.], pH 6.8), and 
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heated at 95°C for 10 min. Samples (30 μg protein/lane) were separated on SDS-PAGE, 
and then transferred to a PVDF membrane (RPN303F; GE Healthcare., Little Chalfont, 
Buckinghamshire, UK). The membrane was washed in TBS-T (0.1% Tween 20 in TBS 
[25 mM Tris-HCl, 137 mM NaCl, pH 7.5]), incubated in blocking buffer (5% nonfat 
dry milk in TBS-T) for 1 h at room temperature. After washing, the membranes were 
incubated with galectin-3 antibody diluted at 1:1000 (sc-20157; Santa Cruz 
Biotechnology Inc., CA, USA), cleaved caspase-3 antibody (#9661; Cell Signaling 
Technology Inc., Beverly, MA, USA) diluted at 1:1000, tumor necrosis factor receptor 
1 (TNFR1) antibody (ab19139; Abcam, Cambridge, UK) diluted at 1:1000, β1 integrin 
antibody (MAB2000; Millipore, Billerica, MA, USA) diluted at 1:1000 or ACTB 
antibody (A2228; Sigma-Aldrich Corp., St. Louis, MO, USA) diluted at 1:10000 for 
overnight at 4°C. After washing with TBS-T, the membrane was incubated with the 
appropriate secondary antibodies (anti-rabbit Ig, HRP-linked whole antibody produced 
by donkey [NA934; Amersham Biosciences Corp., San Francisco, CA, USA; 1:10000] 
for galectin-3, cleaved caspase-3 and TNFR1 protein; anti-mouse Ig, HRP-linked whole 
antibody produced by sheep [no. NA931; Amersham Biosciences Corp.; 1:10000 for β1 
integrin or 1:40000 for ACTB]) for 1 h at room temperature. After washing again with 
TBS-T, the signal was detected by chemiluminescence using Immobilon Western 
Chemiluminescent HRP Substrate (P36599; Millipore, Billerica, MA, USA). ACTB 
protein expression was used as an internal control. The intensity of the immunological 
reaction in the tissues was estimated by measuring the optical density in the defined 
area by computerized densitometry using Image LabTM Software version 4.0 (Bio-Rad 
Laboratories, Inc, Berkeley, CA, USA). 
 
Immunohistochemistry 
The sections, at 5 μm thickness, were de-waxed and washed in 
phosphate-buffered saline. Subsequently the sections were incubated at room 
temperature with 3% hydrogen peroxide in distilled water for 20 min and Avidin/Biotin 
blocking solution (Vector Laboratories Inc., Burlingame, CA, USA) for 15 min for each 
reagent. Then the sections were incubated with normal goat serum for 60 min at room 
temperature followed by galectin-3 antibody (1:200) at 4°C overnight. After washing 
twice in PBS, the sections were incubated with biotinylated anti-rabbit IgG (1:500; 
Vector laboratories Inc., Burlingame, CA, USA) for 60 min at room temperature. The 
reaction sites were visualized using Vectastain ABC Elite kit (Vector Laboratories Inc., 
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Burlingame, CA, USA) for 60 min at room temperature and ImmPACT® 3, 
3’-Diaminobenzidine (DAB) Peroxidase Substrate Kit (Vector Laboratories Inc., 
Burlingame, CA, USA) for 5 min. The sections were counterstained for 2 min with 
haematoxylin and observed under a light microscope (BX51; Olympus Corporation, 
Tokyo, Japan). 
 
WST-1 assay 
WST-1, a kind of MTT [3-(4,5-dimethyl-2 thiazolyl)-2,5-diphenyl-2 
H-tetrazolium bromide], is a yellow tetrazolium salt that is reduced to formazan by live 
cells containing active mitochondria. The culture medium was replaced with 100 μl D/F 
without phenol red medium-BSA, and a 10 μl aliquot (0.3% WST-1, 0.2 mM 
1-methoxy PMS in PBS, pH 7.4) was added to each well. The cells were then incubated 
for 4 h at 38°C. The absorbance was read at 450 nm using a microplate reader (Model 
450; Bio-Rad, Hercules, CA). In this assay, data were expressed as percentages of the 
appropriate control values. 
 
P4 determination 
Concentrations of P4 were determined directly from the cell culture media with 
an enzyme immunoassay, as described previously [30]. The standard curve ranged from 
0.391 to 100 ng/ml, and the median effective dose (ED50) of the assay was 3.5 ng/ml. 
The intra- and interassay coefficients of variation were 5.8% and 9.3%, respectively. 
 
Lectin blotting 
Protein samples were subsequently separated by SDS-PAGE. Separated 
proteins were transferred onto PVDF membrane. The membrane was blocked with 5% 
BSA in TBS-T, and then reacted with 1.0 μg/ml of HRP-conjugated L4-PHA lectin 
(J212; J-OIL MILLS, Tokyo, Japan) in TBS-T for 1 h. After washing again with TBS-T, 
the reactive protein bands were detected by chemiluminescence using Immobilon 
Western Chemiluminescent HRP Substrate. 
 
Galectin-3 overlay assay 
Cell lysates (2.0 mg of protein) were immunoprecipitated with β1 integrin 
antibody and protein-G-beads, as described above. Precipitated proteins were separated 
by SDS-PAGE and subsequently transferred to a PVDF membrane. The membrane was 
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blocked with 5% BSA in TBS-T, and then exposed to biotin-conjugated galectin-3. 
Biotinylated label of glectin-3 was performed using EasyLink Biotin Conjugation Kit 
(ab102865; Abcam), according to the manufacture’s instruction. After washing with 
TBS-T, the membrane was incubated with streptavidin conjugated to HRP. After 
washing again with TBS-T, the reactive protein bands were detected by 
chemiluminescence using Immobilon Western Chemiluminescent HRP Substrate. 
 
Experiment 1: Cyclic changes in the galectin-3 mRNA and protein expressions 
Galectin-3 mRNA and protein expressions of in each CL tissues (Early n=4, 
Developing n=4, Mid n=4, Late n=4, Regressed n=4,) were examined by quantitative 
RT-PCR and western blotting. Galectin-3 protein localization of in each CL tissues 
(Early; n=3, Mid; n=3, Regressed; n=3) was analyzed by immunohistochemistry. 
 
Experiment 2: Effect of luteolytic factors on expression of galectin-3 mRNA and 
protein in cultured mid LSCs 
 To clarify regulatory factors of galectin-3 mRNA and protein in cultured mid 
LSCs, the cells were exposed to 2.3 nM recombinant human TNF (Dainippon 
Pharmaceutical, Osaka, Japan) and/or 2.5 nM recombinant bovine IFNG (kindly 
donated by Dr. S. Inumaru, NIAH, Ibaraki, Japan) or 1.0 μM PGF (P7652; 
Sigma-Aldrich Corp., St. Louis, MO, USA) for 12, 24, 48 and 72 h. The doses for 
treatments were selected based on previous reports [30, 31]. After the culture, the 
expression of galectin-3 mRNA was determined by quantitative RT-PCR. The 
galectin-3 protein expression was assessed by western blotting in cells treated with PGF 
for 48 h. 
 
Experiment 3: Subcellular localization of galectin-3 in the regressed CL and effect 
of PGF on the secretion of galectin-3 in cultured mid LSCs 
To elucidate the subcellular localization of galectin-3 in the regressed CL, the 
regressed CL tissue was fractionated into membrane and cytoplasm fractions. The CL 
tissues were homogenized on ice in the homogenization buffer by a tissue homogenizer 
(Physcotron, NS-50; NITI-ON Inc., Chiba, Japan), followed by a filtration with a metal 
wire mesh (150 μm). For protein analysis, nuclei were removed from the tissue 
homogenates by centrifugation at 700 x g for 5 min. The resultant supernatant was 
fractionated into membrane and cytoplasmic cell fractions by centrifugation at 20,000 x 
- 13 - 
 
g for 1 h. The membrane and cytoplasm fractions were detected expression of galectin-3 
protein by western blotting. Validation of the cell fractionation was performed by 
reprobing with TNFR1 antibody as a plasma membrane marker and ACTB antibody as 
a cytoplasm marker. Since TNFR1 is expressed in the bovine CL [32] and generally 
known as a membrane receptor, TNFR1 antibody was used for plasma membrane 
marker. 
To examine whether PGF induces secretion of the galectin-3 in LSCs, after 48 
h of treatment with PGF (1.0 μM), cultured LSCs were treated with a non-competing 
saccharide, 0.1 M sucrose and a competing saccharide, 0.1 M β-lactose for 4 h. LSCs 
were collected and subsequently analyzed galectin-3 protein by western blotting. 
 
Experiment 4: Effect of galectin-3 on P4 production and cell viability in cultured 
mid LSCs 
 To reveal the effect of galectin-3 on P4 production and cell viability in LSCs, 
the cells were exposed to recombinant galectin-3 (0.01, 0.1, 1.0, 5.0 μg/ml; R&D 
Systems, Inc., Minneapolis, MN, USA) for 24 h. The cell viability was determined by 
Dojindo Cell Counting Kit including WST-1 (No. 345-06463; Dojindo, Kumamoto, 
Japan) as described previously [33]. Progesterone concentrations in the media of LSCs 
were measured by enzyme immunoassay. Expression of cleaved caspase-3 was 
analyzed by western blotting in cells treated with recombinant galectin-3 (1.0 μg/ml) for 
24 h. 
 
Experiment 5: Expression and glycan structure of β1 integrin in bovine CL 
throughout the estrous cycle 
The membrane fractions of the CLs and the LSCs were lysed in a lysis buffer 
consisting of 20 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1.0% Triton X 
100, 10% Glycerol and protease inhibitor cocktail (11 697 498 001; Roche; Basel, 
Switzerland). The lysates (2.0 mg of protein) were incubated with β1 integrin antibody 
and protein-G-beads (MAB2000; Millipore, Billerica, MA, USA) at 4°C for 24 h. The 
beads were washed with lysis buffer three times and immunoprecipitated proteins were 
analyzed by lectin blotting. 
 
Experiment 6: Interaction between β1 integrin and galectin-3 in cultured mid 
LSCs 
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To investigate whether galectin-3 decreases cell viability via β1 integrin in 
LSCs, after 1 h of treatment with β1 integrin neutralizing antibody (MAB1965; 
Millipore, Billerica, MA, USA) or anti-mouse IgG diluted at 1:1000, cultured LSCs 
were treated with recombinant galectin-3 (1.0 μg/ml) for 24 h and the cell viability was 
determined by WST-1. 
 
Statistical analysis 
All experimental data are shown as the mean ± SEM. The statistical 
significance of differences in the expression of galectin-3 mRNA and protein, cleaved 
caspase-3 protein, P4 production and the viability of LSCs were assessed by analysis of 
a one-way ANOVA followed by Bonferroni's multiple comparison test. Probabilities 
less than 5% (P<0.05) were considered significant. 
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RESULTS 
 
Experiment 1: Cyclic changes in the galectin-3 mRNA and protein expressions  
The expressions of galectin-3 mRNA and protein in the bovine CL were higher 
at the regressed luteal stage than at the other luteal stages (Fig. 1A, B; P<0.05). 
Galectin-3 was mainly localized in LSCs and macrophage (Fig. 2).  
 
Experiment 2: Effect of luteolytic factors on expression of galectin-3 mRNA and 
protein in cultured mid LSCs 
The expression of galectin-3 mRNA was significantly increased by a treatment 
with PGF for 48 h (Fig. 3A; P<0.05), but not by TNF and/or IFNG, compared with 
control for 12, 24, 48 and 72 h. The expression of galectin-3 protein was also 
significantly increased by a treatment with PGF for 48 h (Fig. 3B; P<0.05). 
 
Experiment 3: Subcellular localization of galectin-3 in the regressed CL and effect 
of PGF on the secretion of galectin-3 in cultured mid LSCs 
The expression of galectin-3 protein was mainly detected in membrane fraction. 
ACTB was mostly detected in the cytoplasmic fraction and TNFR1 was detected in the 
membrane fraction (Fig. 4A).  
The expression of galectin-3 protein was significantly increased by PGF. 
PGF-induced galectin-3 expression was significantly decreased by β-lactose (Fig. 4B, 
P<0.05).  
 
Experiment 4: Effect of galectin-3 on P4 production and cell viability in cultured 
mid LSCs 
Galectin-3 did not affect P4 production (Fig. 5A), whereas galectin-3 (1.0, 5.0 
μg/ml) significantly decreased the cell viability (Fig. 5B; P<0.05). Furthermore, the 
protein expression of cleaved caspase-3 was significantly increased by galectin-3 (1.0 
μg/ml) (Fig. 5C; P<0.05).  
 
Experiment 5: Expression and glycan structure of β1 integrin in bovine CL 
throughout the estrous cycle 
β1 integrin mRNA and protein in bovine CL were expressed throughout the 
estrous cycle (Fig. 6A, B). β1 integrin in both bovine CL and cultured mid LSCs 
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possessed glycans which galectin-3 binds as revealed by lectin blotting using L4-PHA 
(Fig. 6C).  
 
Experiment 6: Interaction between β1 integrin and galectin-3 in cultured mid 
LSCs 
Galectin-3 bound directly to β1 integrin in the isolated mid luteal cells (Fig.7 
A). Although cultured LSC viability was decreased by galectin-3, the viability of the 
LSC treated with β1 neutralizing integrin antibody was not changed by galectin-3 
compared with control (Fig. 7 B P<0.05).  
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Figure 1. Changes in the relative amounts of galectin-3 expressions. (A) Comparison of 
relative amounts of galectin-3 mRNA determined by quantitative RT-PCR in bovine CL 
tissue throughout the estrous cycle (Early, Days 2-3; Developing, Days 5-6; Mid, Days 
8-12; Late, Days 15-17; Regressed luteal stages [Regress], Days 19-21). Data are the 
mean ± SEM for four samples/stage and are expressed as the relative ratio of galectin-3 
mRNA to MRPL4 mRNA. (B) Representative western blot bands for galectin-3 and 
ACTB. Densitometrically analyzed western blot results in the bovine CL tissue during 
different luteal phases. Data are the mean ± SEM for four samples/stage and are 
expressed as the relative ratio of galectin-3 protein to ACTB protein. Different 
superscript letters indicate significant difference (P<0.05), as determined by ANOVA 
followed by Bonferroni’s multiple comparison test. 
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Figure 2. Representative images of the localization of galectin-3 protein in bovine CL 
throughout the estrous cycle. Black arrows indicate macrophages. Scale bars represent 
50 μm. 
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Figure 3. Effects of luteolytic factors on the expression of galectin-3 mRNA and 
protein in LSCs. (A) LSCs were treated with PGF (1.0 μM) or TNF (2.3 nM) and/or 
IFNG (2.5 nM) for 12, 24, 48 and 72 h. Data are expressed as the relative ratio of 
galectin-3 mRNA to MRPL4 mRNA levels. (B) Representative western blot bands for 
galectin-3 and ACTB in the cells treated with PGF (1.0 μM) for 48 h. The resultant 
signal was detected by chemiluminescence and quantitated by computer-assisted 
densitometry. Data are expressed as the relative ratio of galectin-3 protein to ACTB 
protein. All values are the means ± SEM. All of the experiments were repeated more 
than three times. The data were statistically analyzed using ANOVA followed by 
Bonferroni’s multiple comparison test. Asterisks indicate significant differences 
compared with control for 48 h (P<0.05). 
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Figure 4. (A) Subcellular localization of galectin-3 in the regressed CL. Regressed CL 
was fractionated into the membrane and cytoplasm fractions. Galectin-3 is shown in the 
upper lane. Staining for ACTB and TNFR1 was used to assess the purity of the 
cytoplasm and membrane fractions, respectively. (B) Effect of PGF on the secretion of 
galectin-3 in cultured mid LSCs. Cultured mid LSCs were treated with 0.1 M sucrose 
and 0.1 M β-lactose (Lactose) for 4 h after treated PGF (1.0 μM) for 48 h. The 
galectin-3 protein expression was assessed by western blotting analysis. Representative 
western blot bands for galectin-3 and ACTB are shown. All values are the means ± 
SEM. All of the experiments were repeated more than three times and different 
superscript letters indicate significant difference (P<0.05), as determined by ANOVA 
followed by Bonferroni’s multiple comparison test. 
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Figure 5. Effects of galectin-3 on P4 production (A) and cell viability (B) in LSCs. The 
cells were treated with recombinant galectin-3 (0, 0.01, 0.1, 1.0, 5.0 μg/ml) for 24 h. (C) 
Representative western blot bands for cleaved caspase-3 and ACTB in the cells treated 
with recombinant galectin-3 (1.0 μg/ml) for 24 h. The resultant signal was detected by 
chemiluminescence and quantitated by computer-assisted densitometry. Protein data are 
expressed as the relative ratio of cleaved caspase-3 protein to ACTB protein. All values 
are the means ± SEM. All of the experiments were repeated more than three times. The 
data were statistically analyzed using ANOVA followed by Bonferroni’s multiple 
comparison test (* P<0.05). 
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Figure 6. Changes in the relative amounts and glycan structure of β1 integrin. (A) 
Comparison of relative amounts of β1 integrin mRNA determined by quantitative 
RT-PCR in bovine CL tissue throughout the estrous cycle. Data are the mean ± SEM for 
four samples/stage and are expressed as the relative ratio of β1 integrin mRNA to 
MRPL4 mRNA. (B) Representative western blot bands for β1 integrin and ACTB. 
Densitometrically analyzed western blot results in the bovine CL tissue during different 
luteal phases. (C) L4-PHA lectin blot analysis of glycans attached to β1 integrin. 
Purified β1 integrin proteins were subjected to blotting analysis probed either β1 
integrin antibody or plant lectin (L4-PHA for detecting oligomers of D-GalNac). Data 
are the mean ± SEM for four samples/stage and are expressed as the relative ratio of 
galectin-3 protein to ACTB protein.  
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Figure 7. Interaction between β1 integrin and galectin-3 in cultured mid LSCs. (A) 
Galectin-3 overlay assay of glycans attached to β1 integrin. Immunoprecipitated β1 
integrin proteins were subjected to blotting analysis probed either β1 integrin antibody 
or Biotinylated galectin-3. As shown, biotin-conjugated galection-3 bound to β1 
integrin from the mid LSCs. (B) Cultured mid LSCs were treated with recombinant 
galectin-3 (1.0 μg/ml) for 24 h after treated with β1 integrin function blocking antibody 
or mouse IgG (diluted at 1:1000) for 1 h. All values are the means ± SEM. All of the 
experiments were repeated more than three times, and different superscript letters 
indicate significant difference (P<0.05), as determined by ANOVA followed by 
Bonferroni’s multiple comparison test. 
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Table 1. Primers for Quantitative RT-PCR 
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DISCUSSION 
 
Galectin-3 is a ubiquitously expressed protein that is involved in cell survival 
and death in many cell types [35]. In the mice, since regressing CL consisted of 
galectin-3-positive luteal cells, galectin-3 is suggested to be involved in luteal 
regression [36]. Although galectin-3 has been detected immunohistochemically in the 
bovine CL throughout the estrous cycle [27], its regulatory factor, target protein and 
roles in LSCs are unclear. Galectin-3 is present in the cell nucleus or cytoplasm, on the 
cell surface, and also in the extracellular environment [15]. Galectin-3 has been 
demonstrated to play the conflicting roles in cell viability, i.e. cell survival and 
apoptosis [15]. The two different actions of galectin-3 on cell viability depend on its 
subcellular localization [13]. Intracellular galectin-3 generally protects cells against 
apoptosis through carbohydrate-independent mechanisms, whereas extracellular 
galectin-3 binds to cell surface oligosaccharides and induces apoptosis [14, 21, 22, 37]. 
The major event that causes the structural luteolysis is death of LSCs by apoptosis [5]. 
In the present study, the expression of galectin-3 in the bovine CL was higher at the 
regressed luteal stage than at the other luteal stages, and that its protein was localized in 
LSCs and macrophages (Fig. 1, 2). As galectin-3 is commonly used as a macrophage 
maker [38], galectin-3 positive cells besides LSCs were judged as macrophages. Since 
the bone marrow-derived macrophages of galectin-3-deficient mouse exhibited 
defective phagocytosis of apoptotic cells, galectin-3 in macrophages is thought to play 
important roles of phagocytosis [39]. Moreover, luteolysis involves phagocytic 
elimination of apoptotic luteal cells by luteal macrophages in rat [40]. Based on the 
above findings, galectin-3 may also be required for phagocytosis by macrophages in the 
regressing CL in cattle. 
The localization of galectin-3 on the membrane might not completely be 
supported, because a faint band of β-actin was detected in plasma membrane fraction 
(Fig. 4A). Therefore, I further investigated whether galectin-3 was localized on LSCs 
stimulated by PGF (a mimic luteal regression) (Fig 4B). Galectin-3 binds to 
N-acetyllactosamine (LacNAc) structure in glycans, and lactose is a saccharide which 
has structure similar to LacNAc and inhibits the binding to galectin-3 [13]. On the other 
hand, since sucrose is a saccharide which does not bind to galectin-3, sucrose is 
commonly used as a negative control of lactose [22]. In the present study, the 
expression of galectin-3 protein stimulated by PGF was decreased by lactose but not 
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sucrose (Fig 4B), and the western blot band of membrane fraction was obviously 
stronger than that of cytosol fraction (Fig. 4A). The above findings strongly suggest that 
galectin-3 is mainly localized on the plasma membrane in the regressed CL. 
In various cells types, galectin expression is induced by cytokines as TNF, 
IFNG and interleukin 1 β [41-44]. In luteolysis, TNF and IFNG produced by immune 
cells play an important role [5]. Not only cytokines (TNF and IFNG) but also PGF are 
known as important luteolytic factors [5, 33]. Since galectin-3 expression was higher at 
the regressed luteal stage (Fig. 1, 2), I hypothesized that TNF, IFNG or PGF affect the 
expression and secretion of galectin-3 in LSCs. In the present study, the expression and 
secretion of galectin-3 in LSCs was stimulated by PGF at 48 h. PGF is elevated as a 
series of pulses in uterine venous blood at days 18-19 after ovulation [1]. In addition, 
galectin-3 expression in bovine CL was increased at the regressed stage (Fig. 1). Based 
on the above findings, PGF which triggers the induction of luteolysis during days 18-19 
[1] may stimulate the expression and secretion of galectin-3 by LSCs during days 19-21. 
Furthermore, galectin-3 localized on plasma membrane in the regressed CL may be the 
result of secretion of galectin-3 from LSCs in response to PGF.  
Luteolysis is characterized by a phase of inhibited P4 production (functional 
luteolysis), followed by a phase of decreasing in luteal size (structural luteolysis), when 
cells of the CL undergo apoptosis [1]. P4 production by LSCs treated with galectin-3 
did not change in spite of decreasing LSC viability. There are no reports that galectin-3 
affects a hormone production by any types of cells. One might only suppose that the cell 
death of LSCs started occurring at around 24 h after galectin-3 treatment. Galectin-3 
may contribute to only structural luteolysis, not to functional luteolysis. Galectin-3 
binds to glycoproteins such as integrins, neural cell adhesion molecule and CD98 [35]. 
In addition, integrins are expressed in luteal cells of rodents, and granulosa and theca 
cells of ruminants [23]. β1 integrin is reported to be involved in apoptosis induced by 
galectin-3 in colonic epithelial cells [22]. Based on the above findings, I hypothesized 
that the apoptosis in LSCs induced by galectin-3 requires β1 integrin. As expected, β1 
integrin was expressed and possesses glycans which galectin-3 binds in bovine CL 
throughout the estrous cycle. However, β1 integrin expression and glycan structure did 
not change throughout the estrous cycle (Fig. 6). This may be the reason why luteolysis 
is controlled by the change of galectin-3 expression during the estrous cycle, but not by 
changes in the expression or glycan structure of β1 integrin. I confirmed that galectin-3 
induces LSC death by binding to β1 integrin (Fig. 7), as shown in colon epithelial cells 
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and T cells [14, 22]. Integrins including β1 integrin bind to extracellular matrix 
(fibronectin, collagen), and galectin-3 inhibits the binding of the integrins to the 
extracellular matrix [45]. A variety of cell types undergo apoptosis by lack of 
extracellular matrix attachment, which is termed anoikis [24]. These findings suggest 
that galectin-3 produced by LSCs inhibits binding of integrins to extracellular matrix, 
and induces anoikis in LSCs.   
The overall findings suggest that galectin-3 increased by PGF induces 
apoptosis in bovine LSCs via β1 integrin, contributing to structural luteolysis. 
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SUMMARY 
 
Luteolysis is characterized by a reduction in progesterone (P4) production 
(functional luteolysis) and tissue degeneration (structural luteolysis) in the corpus 
luteum (CL). One of major events during structural luteolysis is luteal cell death. 
Galectin-3, a ubiquitously expressed protein involved in many cellular processes, serves 
as an anti-apoptotic and/or pro-apoptotic factor in various cell types. Although 
galectin-3 is detected in the bovine CL, its role remains unclear. The expression of 
galectin-3 in the bovine CL was higher at the regressed stage than at the other luteal 
stages. Galectin-3 was localized on luteal steroidogenic cells (LSCs). When cultured 
LSCs were exposed to prostaglandin F2α (PGF) for 48 h, the expression and secretion 
of galectin-3 increased. When the cultured LSCs were treated with galectin-3 for 24 h, 
cleaved caspase-3 expression was increased and the cell viability was decreased, 
whereas P4 production did not change. β1 integrin, a target protein of galectin-3, was 
expressed in bovine CL and possessed glycans which galectin-3 binds. Furthermore, 
galectin-3 bound to glycans of luteal β1 integrin. The decreased cell viability of cultured 
LSCs by galectin-3 was suppressed by β1 integrin antibody. The overall findings 
suggest that the secreted galectin-3 stimulated by PGF plays a role in structural 
luteolysis by binding to β1 integrin. 
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CHAPTER 2 
Possible contribution of α2,6-sialylation to luteolysis in cows 
by inhibiting the luteotrophic effects of galectin-1 
 
INTRODUCTION 
 
Luteolysis is characterized by a reduction in progesterone production (functional 
luteolysis) followed by a rapid decrease of the size of the corps luteum (CL) (structural 
luteolysis) [2]. The major cause of structural luteolysis is luteal cell death (apoptosis) 
[1-5]. During structural luteolysis, many cytokines from macrophages and neutrophils 
[9], and nitric oxide from luteal endothelial cells in response to prostaglandin F2α 
(PGF) directly induce apoptosis of cells in the CL [2, 8-11]. However, other factors 
besides these key molecules may also be involved in luteolysis. 
Glycosylation modulates a variety of physicochemical and biological 
properties of proteins such as protein folding, stability, targeting, and ligand binding 
[47-52]. Most membrane proteins including cell surface receptors are glycosylated, and 
glycosylation status is important for their function [53, 54]. However, the role of 
glycosylation in the CL is not clear. Galectins are carbohydrate-binding proteins 
distributed intra- and extra-cellularly [55]. Their carbohydrate-binding specificity for 
β-galactoside is conserved by evolutionarily preserved carbohydrate-recognition 
domains [55]. Extracellular galectins interact with cell surface oligosaccharides and 
form lattices that enhance the resident time of glycoproteins at the cell surface [56]. 
Among 15 members of galectins, galectin-1 is one of the most broadly distributed 
galectins in mammalian tissues, in which it modulates cell proliferation and survival 
[57-59]. Galectin-1 binds to N-acetyllactosamine (LacNAc) residues, which consist of 
galactose β-linked to N-acetylglucosamine, whereas its binding is completely inhibited 
by α2,6-sialylation of galactose [60-62]. ST6Gal-I is a sialyltransferase that catalyzes 
the binding of an α2,6-sialic acid to galactose on glycan branch ends through an 
α2,6-linkage [63, 64]. The addition of α2,6-sialic acid to the terminal galactose of 
glycans masks the galectin recognition sites, and inhibits the role of galectin-1 in 
adhesion, migration, and apoptosis [65]. We recently demonstrated that galectin-1 binds 
to the glycans on the surface of bovine luteal steroidogenic cells (LSCs) in the bovine 
mid CL and increases the viability of LSCs, suggesting that galectin-1 has a 
luteotrophic function in the bovine CL [66]. The protein expression of galectin-1 in the 
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cell membrane fraction is high in the CL during mid-luteal stages while it decreases in 
the regressed CL [66]. The loss of luteotrophic galectin-1 from the cell membrane may 
be due to a decreased ligand-binding ability and accompanied by modifications of 
ligand glycoconjugates such as α2,6-sialylation during luteolysis.   
I hypothesized that the level of α2,6-sialylation is increased by luteolytic 
factors and that this increase inhibits the binding of galectin-1 to glycan, thereby 
weakening the survival signal of galectin-1 during luteolysis. To test this hypothesis, I 
examined 1) cyclic changes in the expression of ST6Gal-I mRNA and the level of 
α2,6-sialylation of glycoproteins in the bovine CL, 2) the effects of luteolytic factors on 
the expression of ST6Gal-I mRNA and the level of α2,6-sialylation in cultured 
mid-LSCs, and 3) Effect of α2,6-sialylation on galactin-1-enhanced viability of cultured 
mid- (Days 8-12 after ovulation) and late- (Days 15-17 after ovulation) LSCs. 
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MATERIALS AND METHODS 
 
Collection of bovine CLs, luteal cell isolation and cell culture 
Collection of bovine CLs, luteal cell isolation and cell culture were conducted 
as described in MATERIALS AND METHODS of chapter 1 (Page 8). 
 
Protein fractionation and extraction 
The CL tissues for western blotting were homogenized on ice in the 
homogenization buffer (300 mM sucrose, 32.5 mM Tris-HCl, 2 mM EDTA, pH 7.4) by 
a tissue homogenizer (Physcotron, NS-50; NITI-ON Inc., Chiba, Japan), followed by 
filtration with a metal wire mesh (grid size 150 μm). For protein analysis, nuclei were 
removed from the tissue homogenates by centrifugation at 700 xg for 5 min. The 
resultant supernatant was fractionated into membrane and cytoplasmic fractions by 
centrifugation at 20,000 xg for 60 min. For protein analysis using LSCs, total cell 
lysates were used. After culture, LSCs were collected and lysed in lysis buffer 
consisting of 20-mM Tris-HCl, pH 7.4, 150-mM NaCl, 1-mM EDTA, 1.0% Triton 
X-100, 10% glycerol, and protease inhibitor cocktail (1697498; Roche, Mannheim, 
Germany). Their protein concentrations were determined by BCA method [67]. The 
proteins were then solubilized in SDS gel-loading buffer (50 mM Tris-HCl, 2% SDS, 
10% glycerol, 1% β-mercaptoethanol, pH 6.8), and heated at 95°C for 10 min. 
Validation of the subcellular fractionation was performed by western blotting using the 
antibodies against tumor necrosis factor receptor 1 (TNFR1; ab19139; Abcam, 
Cambridge, UK) as a plasma membrane marker and β-actin (A2228; Sigma-Aldrich, 
MO, USA) as a cytoplasm marker (data not shown). 
 
Quantitative RT-PCR 
Quantitative RT-PCR was conducted as described in MATERIALS AND 
METHODS of chapter 1 (Page 9) using specific primers for ST6Gal-I from the bovine 
sequence (Table 1).  
 
Western blotting 
Proteins were solubilized in SDS gel-loading buffer, and heated at 95°C for 10 
min. Samples (20 μg protein/lane) were separated on SDS-PAGE, and then transferred 
to a PVDF membrane (RPN303F; GE Healthcare., Little Chalfont, Buckinghamshire, 
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UK). The membrane was washed in TBS-T (0.1% Tween 20 in TBS [25 mM Tris-HCl, 
137 mM NaCl, pH 7.5]) and incubated in blocking buffer (5% nonfat dry milk in 
TBS-T) for 1 h at room temperature. After washing, the membranes were incubated 
with galectin-1 antibody at 1:4,000 (AF1152, R&D Systems, MN, USA) or β-actin 
(ACTB) antibody diluted at 1:10,000 (A2228; Sigma-Aldrich, MO, USA) for overnight 
at 4°C. After washing with TBS-T, the membrane was incubated with the appropriate 
secondary antibodies (HRP-linked donkey anti-goat IgG [no.sc-2020; Santa Cruz 
Biotechnology; 1:5,000 for galectin-1] or HRP-linked sheep anti-mouse IgG [no. 
NA931; Amersham Biosciences Corp.; 1:40,000 for ACTB]) for 1 h at room 
temperature. After washing again with TBS-T, the signal was detected by 
chemiluminescence using Immobilon Western Chemiluminescent HRP Substrate 
(P36599; Millipore, Billerica, MA, USA). β-Actin protein expression was used as an 
internal control for the experiments using total cell lysates. The intensity of the 
immunological reaction in the tissues or cells was estimated by measuring the optical 
density in the defined area by computerized densitometry using Image LabTM Software 
version 4.0 (Bio-Rad Laboratories, Inc, Berkeley, CA, USA). 
 
Lectin blotting 
Protein samples (5 μg/lane) were subsequently separated by SDS-PAGE. 
Separated proteins were transferred onto a PVDF membrane. The membrane was 
blocked with 5% BSA in TBS-T, and then reacted with biotin-conjugated SSA (0.17 
μg/ml) lectin in TBS-T for 1 h. After washing again with TBS-T, the membrane was 
incubated with 0.17 μg/ml of streptavidin conjugated to HRP (#21130; Pierce 
Biotechnology, IL, USA). After washing again with TBS-T, the reactive protein bands 
were detected by chemiluminescence using Immobilon Western Chemiluminescent 
HRP Substrate as described above. 
 
Lectin histochemistry 
The CL tissues (2.0-3.0 g) are classified as early-luteal (n=3), mid-luteal (n=4), 
late-luteal (n=3), and regressing stages (n=5), and fixed with 4% paraformaldehyde for 
histological analysis. The fixed tissues were embedded into paraffin according to the 
conventional method. Five-μm-thick sections were de-waxed and washed in 
phosphate-buffered saline. Subsequently the sections were incubated at room 
temperature with 3% hydrogen peroxide in distilled water for 20 min, and Avidin/Biotin 
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blocking solution (Vector Laboratories Inc., Burlingame, CA, USA) for 15 min for each 
reagent, followed by Carbo-free blocking solution (Vector Laboratories In.) for 60 min. 
Then the sections were incubated with biotin-conjugated SSA lectin (1.0 μg/ml) at 4°C 
overnight. After washing twice in PBS, the reaction sites were visualized using 
Vectastain ABC Elite kit (Vector Laboratories Inc., Burlingame, CA, USA) for 60 min 
at room temperature and ImmPACT® 3, 3’-Diaminobenzidine (DAB) Peroxidase 
Substrate Kit (Vector Laboratories Inc., Burlingame, CA, USA) for 5 min. The sections 
were counterstained for 2 min with haematoxylin and observed under a light 
microscope (BX51; Olympus Corporation, Tokyo, Japan) using 20x object lens. Control 
sections were incubated with PBS instead of SSA, and a disappearance of the signals in 
both endothelial cells and luteal cells was confirmed. LSCs and luteal endothelial cells 
were identified by localization and morphology features of the cells [71, 72]. Since SSA 
lectin reacts against the endothelial cells [73], SSA lectin positive cells besides LSCs 
were judged as luteal endothelial cells. and I referenced that SSA lectin reacts against 
the endothelial cells. 
 
Viability assay 
WST-8, a kind of MTT, is a yellow tetrazolium salt that is reduced to formazan 
by live cells containing active mitochondria. The culture medium was replaced with 100 
μl D/F without phenol red medium-BSA, and a 10 μl WST-8 was added to each well. 
Cells were then incubated for 4 h at 38.5°C. The absorbance was read at 450 nm using a 
microplate reader (Model 450; Bio-Rad, Hercules, CA).  
 
Experiment 1: Cyclic changes in the expression of ST6Gal-I mRNA and the level of 
α2,6-sialylation of glycoproteins in the bovine CL  
ST6Gal-I mRNA and α2,6-sialic acid expressions of in each CL tissues and 
membrane fraction of CL tissues (early n=4, developing n=4, mid n=4, late n=4, 
regressed n=4,) were examined by quantitative RT-PCR and lectin blotting using 
Sambucus Sieboldiana Agglutinin (SSA; J218; J-OIL MILLS, Tokyo, Japan). 
Localization of α2,6-sialic acid in each CL tissues (Early; n=3, mid; n=3, Regressed; 
n=3) was analyzed by lectin histochemistry using SSA. 
 
Experiment 2: Effect of luteolytic factors on the expression of ST6Gal-I mRNA 
and the level of α2,6-sialylation of cultured mid-LSCs  
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To clarify whether luteolytic factors play a role in the expression of ST6Gal-I 
mRNA and the level of α2,6-sialylation in the bovine CL, the cultured mid-LSCs were 
exposed to 2.3 nM recombinant human tumor necrosis factor α (TNFα; Kindly donated 
by Dainippon Pharmaceutical, Osaka, Japan), 2.5 nM recombinant bovine interferon γ 
(IFNG; Kindly donated by Dr. S. Inumaru, NIAH, Ibaraki, Japan), 1.0 μM PGF (P7652; 
Sigma-Aldrich Corp., St. Louis, MO, USA) alone, or TNFα in combination with IFNG 
for 24, 48 and 72 h. Additionally, the cultured mid-LSCs were exposed to 10 ng/ml 
luteinizing hormone (LH: USDA-bLH-B6) and 1.0 μM prostaglandin E2 (PGE: no. 
P0409; Sigma) for 24 h. The doses for treatments were selected based on previous 
reports [30, 31, 68, 69]. After the culture, the expression of ST6Gal-I mRNA was 
determined by quantitative RT-PCR. TNF (2.3 nM) and IFNG (2.5 nM) induces the 
expression of FAS mRNA in cultured LSCs [34]. The induction of the expression of Fas 
mRNA by TNF (2.3 nM) and IFNG (2.5 nM) was confirmed in this experiment. The 
expression of α2,6-sialic acid in total cell lysates was assessed by SSA lectin blotting 
only in cells treated with PGF for 72 h. 
 
Experiment 3: Effect of α2,6-sialylation on galactin-1-enhanced viability of 
cultured mid- and late-LSCs 
The level of α2,6-sialylation of mid- and late-LSCs in total cell lysates was 
measured by SSA lectin blotting. To investigate the effect of galectin-1 on cell viability 
of mid- and late-LSCs, these cells were incubated with or without recombinant 
galectin-1 (1,000 ng/ml; 1152-GA-050/CF; R&D Systems, Inc, Minneapolis, MN) for 
24 h. The cell viability was determined by Methyl tetrazolium (MTT) assay. In my 
previous study, galectin-1 (10, 100, and 1,000 ng/ml) significantly increased the 
viability of cultured LSCs and the greatest increase in the viability of LSCs was 
observed by the treatment with galectin-1 (1,000 ng/ml) [66]. Thus, I used 1,000 ng/ml 
of galectin-1 in the present study. 
To remove sialic acid from cell surface glycoproteins, late-LSCs were treated 
with or without neuraminidase (0.1, 1.0, 10 units/ml; P0720S; New England BioLabs 
Inc., Ipswich, MA) for 1 h and washed. Then, cells were further incubated for 24 h and 
α2,6-sialic acid expression was analyzed by SSA lectin blotting to confirm a reduction 
in the level of α2,6-sialylation by neuraminidase treatment. To examine whether 
α2,6-sialic acid inhibits the effect of galectin-1 on the viability of late-LSCs, cells were 
incubated with or without neuraminidase (10 units/ml) for 1 h and washed. Then cells 
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were further incubated with or without recombinant galectin-1 (1000 ng/ml) for 24 h. 
The cell viability was determined using a WST-8 cell proliferation assay.  
 
Statistical analysis 
All experimental data are shown as the mean ± SEM. The statistical 
significances of differences were assessed by analysis of Student’s t-test, one-way 
ANOVA followed by Dunnett’s multiple comparison test or two-way ANOVA 
followed by Tukey’s multiple comparison test using the GraphPad Prism ver 6.0 
(GraphPad software, San Diego, CA). Probabilities less than 5% (P<0.05) were 
considered statistically significant. 
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RESULTS 
 
Experiment 1: Cyclic changes in the expression of ST6Gal-I mRNA and the level of 
α2,6-sialylation of glycoproteins in the bovine CL 
The expression of ST6Gal-I mRNA in the bovine CL was significantly higher 
during the regressed-luteal stage than during the developing and mid-luteal stages (Fig. 
8A). The level of α2,6-sialylation in the membrane fraction was higher during the 
regressed-luteal stage than during the other luteal stages (Fig. 8B). Lectin 
histochemistry revealed that α2,6-sialylated glycoconjugates were localized to luteal 
endothelial cells throughout the estrous cycle (arrows in Fig. 9). In the regressed-luteal 
stage, α2,6-sialylated glycoconjugates concentrated to the plasma membrane of LSCs 
(Fig. 9).  
 
Experiment 2: Effect of luteolytic factors on the expression of ST6Gal-I mRNA 
and the level of α2,6-sialylation of cultured mid-LSCs  
 The expression of ST6Gal-I mRNA was significantly increased by treatment 
with PGF for 72 h, but it was not affected by treatment with TNFα, IFNG, or a 
combination of TNFα and IFNG for 24, 48 or 72 h (Fig. 10A). Moreover, the 
expression of ST6Gal-I mRNA was not affected by treatment with LH or PGE for 24 h 
(Fig. 14). The level of α2,6-sialylated glycoproteins in total cell lysates was also 
significantly increased by treatment with PGF for 72 h (Fig. 10B). 
 
Experiment 3: Effect of α2,6-sialylation on galactin-1-enhanced viability of 
cultured mid- and late-LSCs 
 The level of α2,6-sialylated glycoproteins of late-LSCs was higher than that of 
mid-LSCs (Fig. 11A). Galectin-1 (1.0 μg/ml) increased the viability of mid-LSCs, while 
it did not affect the viability of late-LSCs (Fig. 11B, C). Neuraminidase treatment (1.0 
and 10 units/ml) decreased the level of α2,6-sialylation in total cell lysates of late-LSCs 
(Fig. 12A). Pretreatment of late-LSCs with neuraminidase (10 units/ml) restored the 
ability of galectin-1 to increase their viability (Fig. 12B). 
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Figure 8. Changes in the relative amounts of the expression of ST6Gal-I mRNA and 
α2,6-sialylated glycoproteins. (A) Comparison of relative amounts of ST6Gal-I mRNA 
determined by quantitative RT-PCR in bovine CL tissue throughout the estrous cycle 
(early [E], Days 2-3; developing [D], Days 5-6; mid [M], Days 8-12; late [L], Days 
15-17; regressed luteal stages [R], Days 19-21). Data are the mean ± SEM for four 
samples/stage and are expressed as the relative ratio of ST6Gal-I mRNA to MRPL4 
mRNA. (B) Representative α2,6-sialic acid specific SSA lectin blotting of membrane 
glycoproteins from CL. Different superscript letters indicate significant difference 
(P<0.05), as determined by ANOVA followed by Tukey’s multiple comparison test. 
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Figure 9. Representative images of the localization α2,6-sialylated glycoconjugates on 
the bovine CL throughout the estrous cycle revealed by SSA lectin histochemistry. 
Black arrows indicate luteal endothelial cells. The mid-CL tissues were used in the 
control sections.  
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Figure 10. Effects of luteolytic factors on the expression of ST6Gal-I mRNA and the 
level of α2,6-sialylated glycoproteins in total cell lysates of mid-LSCs. (A) LSCs were 
treated with TNFα (2.3 nM), IFNG (2.5 nM), TNFα and IFNG or PGF (1.0 μM) for 24, 
48, and 72 h. Data are expressed as the relative ratio of ST6Gal-I mRNA to MRPL4 
mRNA levels. (B) Representative SSA lectin blot analysis for α2,6-sialic acid and 
ACTB in cells treated with PGF (1.0 μM) for 72 h. The resultant signal was detected by 
chemiluminescence and quantitated by computer-assisted densitometry. Data are 
expressed as the relative ratio of α2,6-sialylated proteins to ACTB protein. All values 
are the means ± SEM. All of the experiments were repeated more than three times, and 
the data were statistically analyzed using student t-test and ANOVA followed by 
Dunnett’s multiple comparison test. Asterisks indicate significant differences compared 
with control for 72 h (P<0.05). T+I: TNFα+IFNG treatment. 
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Figure 11. Difference in α2,6-sialylation and the effect of galectin-1 in cultured mid- 
and late-LSCs. (A) Representative SSA lectin blotting of glycoproteins and ACTB in 
total cell lysates of mid- and late-LSCs. (B, C) Mid- and late-LSCs were incubated with 
or without galectin-1 (1.0 μg/ml) for 24 h. All values are the means ± SEM. The data 
were statistically analyzed using student t-tests. Asterisks indicate significant 
differences compared with control (P<0.05).  
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Figure 12. Effect of neuraminidase on the action of galectin-1 in late-LSCs. (A) 
Representative images of SSA lectin blotting and ACTB in total cell lysates of 
late-LSCs cultured for 24 h after the pretreated with or without neuraminidase (0.1, 1.0, 
and 10 units/ml) for 1h. (B) Late-LSCs were pretreated with or without neuraminidase 
(10 units/ml) for 1h, and further incubated with or without recombinant galectin-1 (1.0 
μg/ml) for 24 h. All values are the means ± SEM. Different superscript letters indicate 
significant difference (P<0.05), as determined by ANOVA followed by Tukey’s 
multiple comparison tests. 
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Figure 13. Changes in the relative amounts of galectin-1 protein expression in total 
(cytoplasmic and cell membrane) fraction of the CL tissue. Representative images for 
western blot analysis for galectin-1 and ACTB are shown in the top. Densitometrically 
analyzed western blot results in both cytoplasmic and cell membrane fraction of bovine 
CL tissue throughout the estrous cycle (Early [E], Days 2-3; Developing [D], Days 5-6; 
Mid [M], Days 8-12; Late [L], Days 15-17; Regressed luteal stages [R], Days 19-21) are 
shown in the bottom. Data are the mean ± SEM of three samples/stage and are 
expressed as the relative ratio of galectin-1 protein to ACTB protein. Different 
superscript letters indicate significant difference (P<0.05), as determined by ANOVA 
followed by Tukey’s multiple comparison test. 
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Figure 14. Effects of LH or PGE on the expression of ST6Gal-I mRNA in mid-LSCs. 
LSCs were treated with LH (10 ng/ml) or PGE (1.0 μM) for 24 h. Data are expressed as 
the relative ratio of ST6Gal-I mRNA to MRPL4 mRNA levels. All values are the means 
± SEM. All of the experiments were repeated more than three times. 
 
 
Figure 15. Effects of TNFα and IFNG on the expression of Fas mRNA in mid-LSCs. 
LSCs were treated with TNFα (2.3 nM) and IFNG (2.5 nM) for 24 h. Data are expressed 
as the relative ratio of Fas mRNA to MRPL4 mRNA levels. All values are the means ± 
SEM. The data were statistically analyzed using student t-tests. Asterisks indicate 
significant differences compared with control (P<0.05). 
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Table 2. Primers for real-time PCR 
    Gene Forward and reverse primers (5'-3')  Accession no. Product (bp) 
    ST6Gal-I 
F: ATTGTGTGGGACCCATCTGT  
BC112480 110 
R: TGATCAGGATGCAGCTTACG  
    Fas 
F: TCCAGATCTCACGCAAACAG  
NM174662 150 
R: CAGTTGCCTCCCTTCATCAT  
    MRPL4 
F:GGCTCAAGACCTTCAACCTG  
BC108102 138 
R:GCGTGTAACGTGAGTCATGC  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 46 - 
 
DISCUSSION 
 The present study revealed that α2,6-sialylation increased during luteolysis in 
the bovine CL and that the increase was regulated by luteolytic PGF through enhancing 
the expression of a sialyltransferase, ST6GAL-I in LSCs. An increased α2,6-sialylation 
on membrane glycoprotein of LSCs during the late-luteal stage attenuated the effect of 
galectin-1 on luteal cell viability. Removal of α2,6-sialic acids by a treatment with 
neuraminidase restored the effect of galectin-1, suggesting that α2,6-sialylation is 
involved in the regulation of luteolysis by inhibiting the binding of galectin-1 to the 
glycans. 
As mentioned above, extracellular galectin-1 promotes cell viability in bovine 
LSCs, suggesting that galectin-1 has a luteotrophic function in the bovine CL [66]. In 
that study, I also showed that the amount of galectin-1 on the cell membrane of the CL 
decreased during luteolysis. However, in the present study, the abundance of galectin-1 
in both cytoplasmic and cell membrane fraction of the CL did not change during the 
estrous cycle. This reminds us that the change in the glycan structure to decrease the 
binding of galectin-1 to glycan on cell membrane may contribute to a loss of galectin-1 
on the cell membrane of LSCs during luteolysis. However, the mechanism to inhibit the 
binding of galectin-1 to glycans during luteolysis remained unclear. Galectins have an 
affinity for LacNAc, whereas modifications of LacNAc structure influence the affinity 
for each galectin subtype. It is well known that α2,6-sialylation of the terminal galactose, 
which is catalyzed by ST6GAL-I, interferes with the binding of galectin-1 [60-62]. I 
revealed here that the level of α2,6-sialylation increased during the late-luteal stage and 
was highest during the regressed-luteal stage where galectin-1 expression on cell 
membrane decreased [66]. These findings suggest that α2,6-sialylation on the glycan 
ligand for galectin-1 inhibits the binding of galectin-1 to the glycan, resulting in a 
decreased localization of galectin-1 on cell membrane of LSCs. Consequently, the 
survival signal induced by galectin-1 may become weak in LSCs during luteolysis. In 
ST6Gal-I-deficient mice, the vascularization is decreased, and the platelet endothelial 
cell adhesion molecule (PECAM) which is important for cell adhesion of endothelial 
cells is unable to remain on the cell surface and incompletely transduced inhibitory 
signals such as antiapoptotic role [74]. In the present study, α2,6-sialic acid localized at 
the luteal endothelial cells. These findings suggest that α2,6-sialylation plays important 
roles of vascularization. 
Galectin-1 has a role in a variety of biological processes, such as cell adhesion, 
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invasion, cell migration, cell survival, and cell death [75]. In mouse, galectin-1 strongly 
expresses during luteolysis, and the expression of ST6Gal-I mRNA is enhanced in the 
regressing CL, suggesting that the interaction between galectin-1 and α2,6-sialylation 
plays an important role in luteolysis [76]. Galectin-1 is also likely to have a luteotrophic 
role in the human CL, and an inhibition of the binding of galectin-1 to glycan caused by 
α2,6-sialylation possibly contributes to the induction of luteolysis in women [77]. In the 
bovine CL, galectin-1 increases the viability of mid-LSCs but does not affect the 
viability of late-LSCs which contained abundant α2,6-sialylated glycoproteins, 
suggesting that α2,6-sialylation in late-LSCs attenuates the effect of galectin-1. When 
the late-LSCs were pretreated with neuraminidase to remove sialic acid residues, 
galectin-1 could increase the cell viability in late-LSCs, further supporting a luteolytic 
role of α2,6-sialic acids. 
Expression of ST6GAL-I mRNA was enhanced by PGF but not by other 
luteolytic factors (Fig. 10). In human luteinizing granulosa cells, luteotrophic factors 
―PGE2 and human chorionic gonadotrophin― strongly suppress the expression of 
ST6Gal-I mRNA [77]. However, in the present study, PGE2 and luteinizing hormone 
did not suppress the expression of ST6Gal-I mRNA in bovine LSCs. In contrast, PGF 
significantly enhanced the expression of ST6GAL-I in bovine LSCs, whereas other 
luteolytic factors including TNFα, IFNG had no effect. PGF regulates luteal function by 
activating protein kinase (PK) C pathways in luteolysis [30, 78]. In addition, activation 
of PKC pathway was found to stimulate α2,6-sialylation in Madin-Darby canine kidney 
cells [79]. These findings suggest that activation of the PKC pathway by PGF 
contributes to the increase of α2,6-sialylation in bovine LSCs during luteolysis.  
Although α2,6-sialylation on glycoproteins likely has a role in luteolysis in 
cows, the proteins carrying α2,6-sialic acid are unclear. We previously revealed that 
galectin-1 enhances the cell viability of mid-LSCs by binding to the glycans of vascular 
endothelial growth factor receptor-2 (VEGFR-2), and the protein expression and 
stability of VEGFR-2 on the cell surface require the binding of galectin-1 to glycan of 
VEGFR-2 in bovine LSCs [66]. Since glycosylation of receptors is important in cell 
surface retention of various receptors through interaction with galectins [80], inhibition 
of the binding of galectin-1 to the glycan of VEGFR-2 by α2,6-sialylation may decrease 
in the VEGFR-2-mediated survival signal in LSCs during luteolysis. However, it is 
unlikely that the sugar chain on VEGFR-2 contains abundant α2,6-sialic acids because I 
could not find a band with an approximate molecular weight for VEGFR-2 (220 kDa) in 
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the SSA lectin blotting analysis. Further studies are required to reveal the proteins 
carrying α2,6-sialic acid residues. 
 The overall findings suggest that the α2,6-sialylation stimulated by PGF 
inhibits the interaction between galectin-1 and glycan, contributing to luteolysis by 
reducing the galectin-1 effect on luteal cell viability in cattle. 
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SUMMARY 
 
The corpus luteum (CL) is essential for establishing pregnancy. If pregnancy 
does not occur during the estrus cycle, luteolysis is induced by prostaglandin (PG) F2α 
secreted from the uterus. Galectin-1, a β-galactose-binding protein, is expressed in the 
functional CL of cows, and increases the viability of bovine luteal steroidogenic cells 
(LSCs) by modifying the functions of membrane glycoproteins. The binding of 
galectin-1 to glycoproteins is blocked by α2,6-sialylation of the terminal galactose 
residues of glycoconjugates, which is catalyzed by a sialyltransferase (ST6Gal-I). 
However, the physiological role of α2,6-sialic acid in the bovine CL is unclear. The 
level of α2,6-sialylation of the bovine CL were higher during the regressed-luteal stage 
than other luteal stages. Lectin histochemistry revealed that α2,6-sialylated 
glycoconjugates were localized to luteal endothelial cells throughout the estrous cycle. 
In addition, α2,6-sialylated glycoconjugates concentrated to the membrane of LSCs 
during the regressed-luteal stage. PGF2α treatment for 72 h enhanced the expression of 
ST6Gal-I mRNA and the level of α2,6-sialylated glycoproteins in mid-LSCs. The level 
of α2,6-sialylated glycoproteins of late-LSCs (Days 15-17 after ovulation) was higher 
than that of mid-LSCs (Days 8-12 after ovulation), and galectin-1 increased the viability 
of mid-LSCs but not that of late-LSCs. Furthermore, galectin-1 increased the viability 
of late-LSCs when α2,6-sialic acid residues were removed by neuraminidase. The 
overall findings suggest that α2,6-sialylation stimulated by PGF2α contributes to 
luteolysis by inhibiting the luteotrophic effects of galectin-1 in the bovine CL. 
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CONCLUSION 
 
 The present study investigated the possible contribution of galectins and glycan 
to luteolysis in cows. The first series of experiments indicate that PGF enhanced the 
expression of galectin-3 in cultured bovine LSCs, and galectin-3 binding to the glycan 
on β1 integrin induces apoptosis of bovine LSCs during structural luteolysis. The 
second series of experiments showed that PGF increased the level of α2,6-sialylation, 
and increase in the level of α2,6-sialylation prevented the interaction between galectin-1 
and glycan, contributing to luteolysis by reducing galectin-1 effect of luteal cell 
viability in cattle. 
 Overall results suggest that that the interaction between galectins and glycan 
play a critical role in the regression of bovine CL. Moreover, PGF controlled the change 
in the expression of galectin-3 and the level of α2,6-sialylation, contributing to 
structural luteolysis. 
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ABSTRACT IN JAPANESE 
ウシ黄体における糖鎖および糖鎖結合性タンパク質 galectin の役割に関する 
研究 
 
羽柴 一久 
ウシを含む多くの哺乳動物において、排卵後に形成される黄体は妊娠の維持
と成立に必須の progesterone (P4) を分泌する一過性の内分泌器官である。妊娠
が成立しなかった際には、主に子宮からの prostagrandin F2α (PGF) の作用によ
り黄体は退行する。黄体の退行は P4 分泌の衰退する機能的退行と黄体組織の
死滅する構造的退行の 2 つの側面から成り、構造的退行は黄体を構成する細胞
のアポトーシスおよび卵巣外への流出により起こる。さまざまな組織において
アポトーシスに免疫応答が関与することが明らかにされており、退行期のウシ
黄体において急激な免疫細胞の増加が認められることから、黄体におけるアポ
トーシスに免疫応答の関与する可能性が示唆されている。構造的退行において
免疫細胞が分泌する tumor necrosis factor α (TNF) や interferon γ (IFNG) などの
サイトカインおよび血管内皮細胞が分泌する NO がアポトーシスを誘導する
ことが知られており、様々な因子により黄体の退行は制御されている。 
 糖鎖修飾は、タンパク質のフォールディング、安定性およびリガンド結合な
ど生理的および生物学的な現象に関与している。細胞膜表面受容体を含む多く
の細胞膜タンパク質は、糖鎖修飾を受けておりそのタンパク質の機能に重要で
ある。しかしながら、黄体における糖鎖修飾の役割について詳細な報告はない。 
 Galectin は細胞内外に局在する糖鎖結合性のタンパク質であり、糖鎖中の β 
型結合した galactose に結合するレクチンである。細胞外 galectin は細胞表面の
糖タンパク質の糖鎖に結合することで、そのタンパク質を細胞膜上に保ち、機
能を維持することが報告されている。Galectin には 15 種類のサブタイプが同定
されており、ウシおよびマウス黄体では galectin-1 および -3 が周期的な変化を
伴いながら発現することが報告されているが、その役割は明らかではない。 
Galectin-3 は細胞質、細胞膜表面および細胞外マトリックスに発現し、アポト
ーシスを制御している。Galectin-3 には細胞質型および細胞外型が存在し、細胞
質型 galectin-3 は糖鎖を介さずリン酸化され抗アポトーシスに働く。一方、細
胞から分泌された細胞外型 galectin-3 は β1 integrin を含む膜タンパク質受容体
の糖鎖と結合し細胞のアポトーシスを誘導することが報告されている。本研究
では、ウシ黄体における galectin-3 の役割を解明するために以下の研究を行っ
た。 
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1) 卵巣を肉眼的所見により、排卵日を 0 日として、排卵後の日数で五つの周
期 (黄体初期: Days 2-3、黄体形成期: Days 5-6、黄体中期: Days 8-12、黄体後期: 
Days 15-17、黄体退行期: Days 19-21) に分類した。その後、各周期における黄体
組織の  galectin-3 の  mRNA およびタンパク質発現を定量的  RT-PCR 法、
Western blot 法によりそれぞれ検討した。また、発情周期を通じた黄体組織を用
いて、galectin-3 タンパク質の局在を免疫組織化学により検討した。2) ウシ中期
黄体から単離した黄体細胞を 24 h 培養後、新しい培養液と交換し以下の実験に
供した。黄体退行因子である TNF 2.3 nM、IFNG 2.5 nM、PGF 1.0 μM を単独ま
たは組み合わせて添加し、さらに 12、24、48、72 h 培養後の galectin-3 mRNA お
よびタンパク質発現を調べた。3) Galectin-3 の分泌に及ぼす PGF の影響を検討
するために、PGF を添加し 48 h 培養後、galectin-3 が結合する糖鎖と競合する 
lactose (100 μM) を添加し、さらに 4 h 後の galectin-3 タンパク質発現を調べた。
4) 発情周期を通じた黄体組織における β1 integrin mRNA およびタンパク質発
現を調べた。また、各発情周期における黄体組織および黄体細胞から免疫沈降
法を用いて β1 integrin タンパク質を回収後、その糖鎖構造を L4-PHA レクチン
を用いて調べ、galectin-3 の β1 integrin への結合能を overlay assay により検討
した。さらに、黄体細胞に β1 integrin 抗体 (1.0 ng/ml) 添加 1 h 後、galectin-3 
(1.0 μg/ml) を添加し 24 h 後の細胞生存率を調べた。 
1) 発情周期を通じた黄体組織において galectin-3 mRNA およびタンパク質
発現量は、他の周期と比較して退行期において有意に高かった。また、galectin-3 
タンパク質は黄体細胞に局在していた。2) Galectin-3 mRNA およびタンパク質
の発現量は、control と比較して PGF 添加 48 h 後において有意に増加した。ま
た、全ての時間において galectin-3 mRNA 発現量は TNF および IFNG 添加に
よって変化しなかった。3) PGF により増加した galectin-3 タンパク質発現量は 
lactose 添加により低下した。4) 発情周期を通じて β1 integrin mRNA およびタ
ンパク質発現量に変化はなく、β1 integrin は galectin-3 結合性の糖鎖を有してい
た。さらに、galectin-3 は β1 integrin に対する結合能を有していた。細胞生存率
は galectin-3 添加区と比較して、β1 integrin 抗体添加後 galectin-3 を添加した区
において有意に増加した。これらのことから、ウシでは子宮からの PGF により
黄体細胞の galectin-3 発現および分泌が促進され、galectin-3 が β1 integrin の糖
鎖に結合することで黄体細胞の死を誘導する可能性が示された。 
ウシにおいて、galectin-1 は機能的黄体に発現しており細胞膜糖タンパク質の
機能を調節することによって黄体細胞の生存率を増加させる。Galectin-1 の糖タ
ンパク質糖鎖への結合は、糖鎖の末端に存在する galactose に sialyltransferase 
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(ST6Gal-I) により α2,6-sialic acid が付加 (α2,6-sialylation) されることで阻害さ
れる。しかしながら、ウシ黄体において α2,6-sialylation の役割について詳細は
明らかではない。本研究では、黄体細胞における α2,6-sialylation が退行因子に
より増加し、増加した α2,6-sialic acid が galectin-1 および糖鎖との結合を阻害
することで、galectin-1 の生存シグナルを減少させるという仮説を立てた。この
仮説を証明するために、以下の研究を行った。 
1) 発情周期を通じた黄体組織における  ST6Gal-I mRNA 発現を定量的 
RT-PCR で調べ、糖タンパク質の α2,6-sialylation レベルを SSA レクチンを用
いたレクチンブロットにより解析すると共に局在についても調べた。2) 中期黄
体細胞に黄体退行因子である TNF、IFNG、PGF を単独または組み合わせて添
加し、さらに  24、 48 および  72 h 培養後の  ST6Gal-I mRNA ならび 
α2,6-sialylation レベルを調べた。 3) 培養中期および後期黄体細胞の 
α2,6-sialylation レベルを調べ、それぞれの細胞に galectin-1 (1000 ng/ml) を添加
し 24 h 後の細胞生存率を測定した。また、後期黄体細胞に sialic acid 分解酵素
である neuraminidase (10 units/ml) を添加し 1 h 後さらに galectin-1 を添加し 
24 h 後の α2,6-sialylation レベルおよび細胞生存率を調べた。 
1) 発情周期を通じて ST6Gal-I mRNA 発現量は、形成期および中期と比較し
て退行期において増加した。糖タンパク質の α2,6-sialylation レベルもまた、退
行期に増加しており、黄体細胞の細胞膜にその局在が認められた。2) 黄体細胞
における ST6Gal-I mRNA 発現量および α2,6-sialylation レベルは PGF 添加後 
72 h において有意な増加が認められたが、 TNF および IFNG の単独または組
み合わせ添加区における 24、48 および 72 h の培養では変化は認められなかっ
た。3) 後期黄体細胞における α2,6-sialylation レベルは、中期黄体細胞と比較し
て高かった。また、galectin-1 は中期黄体細胞の生存率を増加させたが、後期黄
体細胞の生存率は増加させなかった。Neuraminidase は、後期黄体細胞の 
α2,6-sialylation レベルを減少させ、galectin-1 は neuraminidase 処理した後期黄
体細胞の生存率を増加させた。これらのことから、黄体細胞において PGF によ
り増加した α2,6-sialylation は、galectin-1 および糖鎖の結合を阻害することで、
galectin-1 の誘導する生存シグナルを減少させ、黄体退行に関与することが示唆
された。 
本研究より、ウシにおいて galectin および糖鎖の相互作用が黄体退行を調節
していることが示された。さらに PGF は黄体における galectin-3 発現および 
α2,6-sialylation を増加させることで構造的黄体退行を促進することが明らかと
なった。 
